| 应用 |
A c-Abl, Src-Abl, and Bcr-Abl inhibitor |
| 产品介绍 |
Bosutinib (SKI-606) is a potent c-Abl, Bcr-Abl, and Src-Abl kinase inhibitor, shown to effectively interfere with the progress of chronic myelogenous leukemia (CML). In a competitive study with Imatinib, Bosutinib was shown to inhibit Bcr-Abl kinase activity in CD34+ CML cells more potently than Imatinib. Activity of Src-Abl has been implicated in the development of other non-CML malignancies, and Bosutinib has demonstrated in studies to suppress breast cancer growth and migration. |
| 合法信息 |
Sold for research purposes under agreement from Pfizer Inc. - Not for human or veterinary use. |
| 备注 |
Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM, respectively. |
| 生化机理 |
Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM, respectively.Bosutinib (SKI-606) is an orally active; dual Src/Abl tyrosine kinase inhibitor with potent antiproliferative activity. It does not appear to inhibit c-Kit and PDGRF, which are thought to be the cause of numerous side effects in anticancer treatment with some other tyrosine kinase inhibitors. |
| 别名 |
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile;SKI-606;WAY-173606;伯舒替尼;SKI-606;WAY-173606 |
